ESPR went from Private to Public when it IPO'd onto the Nasdaq in 2013. They had already completed some Phase 2 studies at the point of their IPO and their price per share remained more or less flatlined at the IPO price of ~$14 USD for over a year after the initial IPO. ESPR's drug, ETC-1002 is nowhere near the same type of drug as RVX-208, other than they are both small orally available molecules. Just because they both affect plasma lipoproteins doesn't make them similar. They target different classes of lipoproteins, which rely on entirely different cellular and physiolgical mechanisms for lipoprotein assembly, secretion and clearance.

BearDownAZ